Drug eluting stents based on Poly(ethylene carbonate): Optimization of the stent coating process

被引:32
作者
Bege, Nadja [1 ]
Steinmueller, Sven Ole [2 ]
Kalinowski, Marc [3 ]
Reul, Regina [1 ]
Klaus, Sebastian [4 ]
Petersen, Holger [5 ]
Curdy, Catherine [5 ]
Janek, Juergen [2 ]
Kissel, Thomas [1 ]
机构
[1] Univ Marburg, Dept Pharmaceut & Biopharm, D-35037 Marburg, Germany
[2] Univ Giessen, Inst Phys Chem, D-6300 Giessen, Germany
[3] Univ Hosp Giessen & Marburg, Dept Diagnost Radiol, Marburg, Germany
[4] Eucatech AG, Rheinfelden, Germany
[5] Novartis Pharma AG, Basel, Switzerland
关键词
DES; PEC; TOF-SIMS; Spray-coating; Late stent thrombosis; Paclitaxel; CORONARY STENT; BARE-METAL; PACLITAXEL; MECHANISMS; RELEASE; THROMBOSIS; DELIVERY; IMPLANTATION; SIROLIMUS; SAFETY;
D O I
10.1016/j.ejpb.2011.12.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
First generation drug eluting stents (DES) show a fivefold higher risk of late stent thrombosis compared to bare metal stents. Therefore, new biodegradable and biocompatible polymers for stent coating are needed to reduce late stent thrombosis. In this study, a reproducible spray-coating process for stents coated with Poly(ethylene carbonate), PEC, and Paclitaxel was investigated. PEC is a biocompatible, thermoelastic polymer of high molecular weight. The surface degradation of PEC is triggered by superoxide anions produced by polymorphonuclear leukocytes and macrophages during inflammatory processes. Stents with different drug loading were reproducibly produced by a spray-coating apparatus. Confocal laser scanning micrographs of fluorescent dye loaded stents were made to investigate the film homogeneity. The abluminal stent site was loaded more than the luminal site, which is superior for DES. The deposition of the layers was confirmed by TOF-SIMS investigations. Referring to the stent surface, the drug loading is 0.32 mu g (+/- 0.05) (once coated), 0.53 mu g (+/- 0.11) (twice coated), or 0.73 mu g (+/- 0.06) (three times coated) Paclitaxel per mm(2) stent surface. The in vitro release mechanism during non-degradation conditions can be explained by diffusion-controlled drug release slightly influenced by swelling of PEC, revealing that 100% of the loaded Paclitaxel will be released via diffusion within 2 months. So, the in vivo release kinetic is a combination of diffusion-controlled drug release and degradation-controlled drug release depending on the presence or absence of superoxide anions and accordingly depending on the presence or absence of macrophages. We conclude that the specific release kinetics of PEC, its biocompatibility, and the favorable mechanical properties will be beneficial for a next generation drug eluting stent meriting further investigations under in vivo conditions. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:562 / 570
页数:9
相关论文
共 39 条
[1]   New Drug-Eluting Stents An Overview on Biodegradable and Polymer-Free Next-Generation Stent Systems [J].
Abizaid, Alexandre ;
Costa, J. Ribamar, Jr. .
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2010, 3 (04) :384-393
[2]   Poly(ethylene carbonate)s, part I: Syntheses and structural effects on biodegradation [J].
Acemoglu, M ;
Nimmerfall, F ;
Bantle, S ;
Stoll, GH .
JOURNAL OF CONTROLLED RELEASE, 1997, 49 (2-3) :263-276
[3]   Mechanisms of controlled drug release from drug-eluting stents [J].
Acharya, Ghanashyam ;
Park, Kinam .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (03) :387-401
[4]  
[Anonymous], 2011, MONOGRAPHS PACLITAXE
[5]   Biodegradable Poly(ethylene carbonate) Nanoparticles as a Promising Drug Delivery System with "Stealth" Potential [J].
Bege, Nadja ;
Renette, Thomas ;
Jansch, Mirko ;
Reul, Regina ;
Merkel, Olivia ;
Petersen, Holger ;
Curdy, Catherine ;
Mueller, Rainer H. ;
Kissel, Thomas .
MACROMOLECULAR BIOSCIENCE, 2011, 11 (07) :897-904
[6]   In vitro and in vivo evaluation of the safety and stability of the TAXUS® Paclitaxel-Eluting Coronary Stent [J].
Boden, Mark ;
Richard, Robert ;
Schwarz, Marlene C. ;
Kangas, Steve ;
Huibregtse, Barbara ;
Barry, James J. .
JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, 2009, 20 (07) :1553-1562
[7]   Stent thrombosis late after implantation of first-generation drug-eluting stents - A cause for concern [J].
Camenzind, Edoardo ;
Steg, P. Gabriel ;
Wijns, William .
CIRCULATION, 2007, 115 (11) :1440-1455
[8]   Clinical end points in coronary stent trials - A case for standardized definitions [J].
Cutlip, Donald E. ;
Windecker, Stephan ;
Mehran, Roxana ;
Boam, Ashley ;
Cohen, David J. ;
van Es, Gerrit-Anne ;
Steg, P. Gabriel ;
Morel, Marie-angele ;
Mauri, Laura ;
Vranckx, Pascal ;
McFadden, Eugene ;
Lansky, Alexandra ;
Hamon, Martial ;
Krucoff, Mitchell W. ;
Serruys, Patrick W. .
CIRCULATION, 2007, 115 (17) :2344-2351
[9]   In vivo biocompatibility and biodegradation of poly(ethylene carbonate) [J].
Dadsetan, M ;
Christenson, EM ;
Unger, F ;
Ausborn, M ;
Kissel, T ;
Hiltner, A ;
Anderson, JM .
JOURNAL OF CONTROLLED RELEASE, 2003, 93 (03) :259-270
[10]   Pathological mechanisms of fatal late coronary stent thrombosis in humans [J].
Farb, A ;
Burke, AP ;
Kolodgie, FD ;
Virmani, R .
CIRCULATION, 2003, 108 (14) :1701-1706